Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report
Por:
Arreola-Mora C., Silva-Pereyra J., Fernández T., Paredes-Cruz M., Bertado-Cortés B., Grijalva I.
Publicada:
1 feb 2019
Resumen:
Background: A high percentage of patients with multiple sclerosis
present cognitive alterations. Because 4-aminopyridine improves nerve
conduction and efficient synaptic connection could improve cognitive
dysfunction.
Objective: To evaluate the efficacy on cognitive performance and safety
of 4-aminopyridine administered to patients with relapsing-remitting
multiple sclerosis.
Methods: A randomized, double-blind, placebo controlled clinical trial
was conducted in patients with relapsing-remitting multiple sclerosis
diagnosis according to the McDonald criteria. At the beginning and at
the end of the treatment different tests were used to assess cognitive
performance. Subsequently, patients were randomized 1:1 to receive
treatment or placebo. A bootstrap-t test was proposed to test the
effectiveness of cognitive performance, considering a p-value < 0.05 as
statistically significant.
Results: Twenty-four patients were recruited of which 21 completed the
trial, 11 with 4-aminopyridine and 10 with placebo treatment. No
significant differences between groups in the initial assessments were
observed. In terms of efficacy, the experimental group achieved
significantly higher scores in attention span, verbal fluency, planning
and graphics and constructive motion.
Conclusions: 4-aminopyridine proved to be an effective treatment on
cognitive aspects in patients with relapsing-remitting multiple
sclerosis. Drug doses were shown to be safe with mild to moderate
adverse events.
Filiaciones:
Arreola-Mora C.:
Laboratorio de Neurometría, Proyecto de Neurociencias, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico
Unidad de Investigación Médica de Enfermedades Neurológicas, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Cuauhtémoc 330. Col. Doctores. C. P, Mexico City, 06720, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Lab Neurometria, Proyecto Neurociencias, Mexico City, DF, Mexico
Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Unidad Med Alta Especialidad,Unidad Invest Med En, Cuauhtemoc 330 Col Doctores, Mexico City 06720, DF, Mexico
Silva-Pereyra J.:
Laboratorio de Neurometría, Proyecto de Neurociencias, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Lab Neurometria, Proyecto Neurociencias, Mexico City, DF, Mexico
Fernández T.:
Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus UNAM-UAQ, Juriquilla, Queretaro, Mexico
Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Conductual & Cognit, Campus UNAM UAQ, Juriquilla, Queretaro, Mexico
Paredes-Cruz M.:
Unidad de Investigación Médica de Enfermedades Neurológicas, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Cuauhtémoc 330. Col. Doctores. C. P, Mexico City, 06720, Mexico
Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Unidad Med Alta Especialidad,Unidad Invest Med En, Cuauhtemoc 330 Col Doctores, Mexico City 06720, DF, Mexico
Bertado-Cortés B.:
Departamento de Neurología, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Dept Neurol,Unidad Med Alta Especialidad, Mexico City, DF, Mexico
Grijalva I.:
Unidad de Investigación Médica de Enfermedades Neurológicas, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Cuauhtémoc 330. Col. Doctores. C. P, Mexico City, 06720, Mexico
Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Unidad Med Alta Especialidad,Unidad Invest Med En, Cuauhtemoc 330 Col Doctores, Mexico City 06720, DF, Mexico
|